Drug Trial Radar · NCT07250737
Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Avidity Biosciences, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Clinigen Healthcare Limited
- First posted
- Nov 26, 2025
Design
- Study type
- Expanded access
- Who can join
- Male only, from 2 years
Summary
As written by the sponsor on the registry.
The purpose of this Managed Access Program is to allow access to delpacibart zotadirsen (AOC 1044) for eligible patients diagnosed with DMD mutations amenable to exon 44 skipping. The patient's Administering Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.
Conditions
- Muscular Disorders, Atrophic
- Muscular Diseases
- Musculoskeletal Diseases
- Neuromuscular Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Muscular Dystrophies
- Muscular Dystrophy, Duchenne
Interventions
delpacibart zotadirsenDrug
Del-zota is administered as an IV infusion every 6 weeks. Doses are administered based on body weight.
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama · Available
Arkansas Children's Hospital
Little Rock, Arkansas · Available
UCI Alpha Clinic
Irvine, California · Available
Lucille Packard Children's Hospital at Stanford
San Carlos, California · Available
UC San Diego Health
San Diego, California · Available
Connecticut Children's Medical Center
Hartford, Connecticut · Available
Rare Disease Research
Kissimmee, Florida · Available
Nicklaus Children's Hospital
Miami, Florida · Available
Rare Disease Research
Atlanta, Georgia · Available
University of Kansas Medical Center
Kansas City, Kansas · Available
UMass Memorial Health Care
Worcester, Massachusetts · Available
Gillette Children's
Saint Paul, Minnesota · Available
Washington University
St Louis, Missouri · Available
Rare Disease Research
Iselin, New Jersey · Available
Rare Disease Research
Hillsborough, North Carolina · Available
Nationwide Children's Hospital
Columbus, Ohio · Available
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Available
University of Pennsylvania
Philadelphia, Pennsylvania · Available
Prisma Health-Midlands Children's Hospital
Columbia, South Carolina · Available
Neurology & Neuromuscular Care Center
Flower Mound, Texas · Available
UTHealth
Houston, Texas · Available
University of Vermont Medical Center
Burlington, Vermont · Available
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.